“Glow” is a compounded injectable that combines GHK-Cu with BPC-157 and TB-500, though the exact formula varies by seller. GHK-Cu has some human data, mostly from topical creams for skin. BPC-157 and TB-500 have almost no controlled human trials. No study has tested the blend itself, and none of its three ingredients is an FDA-approved drug.[1][3][8]
Glow sits at the busy intersection of skincare and the injectable-peptide market. It is sold as a way to improve skin from the inside, with a recovery story attached. This page takes each ingredient separately, grades the human evidence behind it, sets out exactly where each one stands with the FDA as of October 2026, and explains why there is no dose we can responsibly give you. If you want the single-ingredient detail, our GHK-Cu evidence review, BPC-157 evidence review and TB-500 evidence review go deeper.
What is in the Glow blend, and does every seller use the same formula?
No. “Glow” is a marketing name, not a regulated product, so there is no reference formula a pharmacy has to match. The common version pairs three peptides. One provider we review, Live Vital, describes its Glow as a physician-prescribed compounded blend of GHK-Cu, BPC-157 and TB-500 and says the dose and schedule are set by its physician after intake. Other sellers use different ratios or fold in extra ingredients. Before comparing prices, ask for the milligrams of each peptide per vial and the name of the compounding pharmacy. Without both, two products called Glow may not be the same thing.
| Ingredient | What it is | Best human evidence | Evidence grade |
|---|---|---|---|
| GHK-Cu | Copper-binding tripeptide found naturally in plasma | Small studies of topical creams for skin aging | Low (topical); none for injection |
| BPC-157 | Synthetic 15-amino-acid fragment of a gastric protein | 12-patient knee chart review; 2-person IV safety pilot | Very low |
| TB-500 | Synthetic fragment of thymosin beta-4 | None for the fragment; full-length protein tested as eye drops | None for TB-500 itself |
| The blend | Seller-defined combination of the three | No study of any kind | None |
What does GHK-Cu actually do for skin and hair?
GHK-Cu is the strongest ingredient in the blend. It is a tripeptide (glycine, histidine, lysine) bound to copper that occurs naturally in human plasma, and its levels fall with age. In cell and animal work it stimulates collagen and glycosaminoglycan synthesis and supports wound repair. Gene-expression analyses suggest it shifts the activity of many genes involved in tissue remodeling.[1][2]
The human data are thinner than that list suggests. The controlled skin studies summarized in these reviews are small, mostly older trials of topical creams and serums applied to facial skin, with outcomes such as wrinkle depth, skin density and laxity measured over weeks.[2] Those reviews were written by Loren Pickart, who discovered the peptide, which is worth knowing when weighing their tone. We found no published controlled trial of injected GHK-Cu for skin or hair. So the claim that Glow works on skin “from the inside” borrows evidence from a different route. The hair claims rest on lab and animal work.[1] For concentrations used on skin, see our GHK-Cu dosage guide. For the full topical picture, see peptides for skin.
Is there human evidence for BPC-157 or TB-500?
Very little. A 2025 systematic review of BPC-157 in orthopedic sports medicine screened 544 records and included 36 studies: 35 preclinical and 1 clinical.[3] That clinical study was a retrospective chart review from a single Florida clinic. Of 12 patients given BPC-157 by knee injection, 11 reported meaningful pain relief. There was no control group, no blinding, and pain was rated by phone survey months later.[4] The same group later published an IRB-approved pilot in which two adults received IV BPC-157 (10 mg, then 20 mg) without measurable changes in heart, liver, kidney, thyroid or glucose markers.[5] Two people over two days can tell you very little about safety. The systematic review itself concluded that no clinical safety data exist.[3]
TB-500 has a naming problem. Thymosin beta-4 is a 43-amino-acid protein with a real clinical-trial history. Phase 2 trials tested it as eye drops for dry eye and as a topical gel for skin wounds.[6] In one small randomized dry-eye trial of 9 patients, the eye drops cut ocular discomfort by 35.1% versus vehicle at day 56 (p = 0.0141).[7] But TB-500, as the FDA itself describes it, is a seven-amino-acid fragment (LKKTETQ).[8] The fragment is not the protein, and none of those trials injected it. How the two compounds are usually combined is covered in our BPC-157 and TB-500 blend review.
What doses are sellers using, and why is there no validated dose?
We do not publish a Glow dose, and there is a reason. A dose is validated when trials compare amounts in people and measure benefit against harm. That has never happened for this blend, or for injected GHK-Cu, BPC-157 or TB-500 on their own. The milligram figures in circulation come from vendors, forums and clinicians' own protocols. In the published research, BPC-157 doses were mostly scaled up from rodent studies. TB-500 doses are borrowed from studies of a different molecule. Injected GHK-Cu has no human dosing study at all.
Live Vital, for example, does not print a fixed dose on its Glow page. It says its physician personalizes the dose and schedule after intake. That is how the product should be handled, but it also tells you something: the prescriber is working without a dose-finding trial. If you are given a vial to reconstitute, the peptide reconstitution calculator handles the arithmetic for the prescription you were given. It cannot tell you whether that prescription is right.
What are the side effects and unknowns?
The honest list has two parts. The first is what sellers disclose. Live Vital names injection-site redness or irritation, rare temporary skin discoloration, nausea, headache and fatigue. It also lists people who should talk to a clinician first: anyone with active cancer or a history of it, copper sensitivity or Wilson disease, pregnancy, or liver or kidney disease. The cancer caution has a basis. BPC-157 promotes new blood vessel growth (angiogenesis) in animal studies, and that is a theoretical concern wherever a tumor might exist.[3]
The second part is what nobody has measured. The FDA's own notes say compounded injectable GHK-Cu may carry a risk of immunogenicity, meaning an unwanted immune reaction. It attributes this to the peptide's tendency to aggregate and to peptide-related impurities. It flags a similar immunogenicity concern for BPC-157 by certain routes.[8] No study has looked at what happens when three such peptides share one vial, or at stability, interactions or long-term use. For single-ingredient side-effect detail, see GHK-Cu side effects and BPC-157 side effects.
Is the Glow blend legal to compound in 2026?
It sits in a gray zone, and the status differs by ingredient. A pharmacy compounding under section 503A may generally use a bulk substance only if it is part of an approved drug, has a USP monograph, or appears on the FDA's 503A bulks list. While nominations are reviewed, FDA's interim policy sorts substances into categories. None of Glow's three ingredients is on the bulks list. Here is where each stood on FDA.gov when we read it on October 2, 2026:
| Ingredient | FDA-approved drug? | 503A compounding status on FDA.gov |
|---|---|---|
| GHK-Cu (injectable) | No | Nominated but withdrawn (April 2026). FDA flags an immunogenicity risk from aggregation and impurities. |
| GHK-Cu (non-injectable) | No | Category 1, under evaluation (restored May 2026). FDA plans to consult its advisory committee before the end of February 2027. |
| BPC-157 | No | Nominated but withdrawn (April 2026). Advisory committee voted to recommend it for the bulks list in July 2026; FDA has not acted. |
| TB-500 (thymosin beta-4 fragment) | No | Nominated but withdrawn (April 2026). Same July 2026 advisory recommendation; FDA has not acted. |
Two details matter. First, the injectable form of GHK-Cu, which is the form used in Glow, has a different status from creams. The FDA restored only the non-injectable form to Category 1 after one nominator clarified it meant to withdraw only the injectable route.[9] Second, “nominated but withdrawn” is not approval. In April 2026 the FDA moved BPC-157, TB-500, injectable GHK-Cu and more than a dozen other substances off Category 2 because their nominations were withdrawn.[8] In July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 and TB-500 to the bulks list. Those votes are advisory, and the list has not changed.[10][11] Our peptide legality guide tracks these changes.
Glow vs KLOW: what is the difference?
KLOW is Glow plus a fourth peptide, KPV, a three-amino-acid fragment of alpha-melanocyte-stimulating hormone sold for its anti-inflammatory effects. KPV adds an ingredient with no published human trials. The FDA notes it has not identified any human exposure data for drug products containing KPV.[8] Our KLOW peptide blend review covers it in full. For a side-by-side of two of the ingredients, see BPC-157 vs GHK-Cu.
How do telehealth providers offer Glow, and what does it cost?
Through a prescription, after an online intake. Live Vital lists Glow on its public site (read October 2, 2026) at $449 for a 10-week protocol, which it presents as $149 a month. Over 30 days, that works out to about $192. Live Vital is a commercial partner of Aminoscope, which we disclose. Our Live Vital review covers its care model and pricing. Other providers that sell single peptides and blends are on our peptide therapy provider list, where partners are listed first. For what single-ingredient GHK-Cu costs, see the GHK-Cu cost guide.
The bottom line
Glow packages one ingredient with modest topical evidence and two with almost none, delivered by a route that none of the three has been tested by, in a combination no one has studied. That does not prove it fails. It means anyone selling a specific result is reaching past the data. If you choose it anyway, get it on a prescription, from a named US pharmacy, with a clinician who knows your history. Remember that the FDA's compounding status for all three ingredients is still unsettled.
